FDA panel votes in favor of Spark’s blindness gene therapy
October 17, 2017
Source: cnbc
1,050
Spark Therapeutics Inc's experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded on Thursday, paving the way for the first U.S. gene therapy for an inherited disease.
The panel voted unanimously in favor of the treatment, Luxturna, which is designed to treat inherited retinal diseases caused by defects in a gene known as RPE65, which tells cells to produce an enzyme critical to normal vision.
The FDA is not obliged to follow the recommendations of its advisers but typically does. (Reporting by Toni Clarke in Washington; Editing by Steve Orlofsky)
By Ddu
Copyright©2024 Ddu. All rights reserved.
Read more on
- Could epigenome editing prevent developmental disorders? December 13, 2019
- Drugdu.com’s 4 most Popular Veterinary APIs and Veterinary medicine Suppliers September 6, 2018
- 4 Pharmaceutical Machinery Packaging and Materials Suppliers September 6, 2018
- 3 ENT Equipment and Medical Anaesthesia Equipment Suppliers September 6, 2018
- Need Natural Plant Extracts? Here are 4 Suppliers! September 6, 2018
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
